Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome

Figure 1 Kaplan-Meier curves specifying survival for liver related death, liver decompensation, hepatocellular carcinoma and a composite end point as a function of baseline Hepascore in the whole cohort. A: Time to composite end point using baseline Hepascore (P < 0.001); B: Time to LRD according to Hepascore (P < 0.001); C: Time to LD according to Hepascore (P < 0.001); D: Time to HCC according to Hepascore (P < 0.001). LRD: Liver related death; LD: Liver decompensation; HCC: Hepatocellular carcinoma.

Figure 2 Kaplan-Meier curves specifying survival for liver related death, liver decompensation, hepatocellular carcinoma and a composite end point as a function of Delta Hepascore in the cohort with a baseline Hepascore > 0. 75. A: Composite end point according to delta Hepascore, with a baseline Hepascore result of > 0.75 (P = 0.004); B: LRD according to delta Hepascore, with a baseline Hepascore result of > 0.75 (P = 0.048); C: LD according to delta Hepascore, with a baseline Hepascore result of > 0.75 (P = 0.001); D: HCC according to delta Hepascore, with a baseline Hepascore result of > 0.75 (P = 0.178). LRD: Liver related death; LD: Liver decompensation; HCC: Hepatocellular carcinoma.

Figure 3 Kaplan-Meier curves specifying survival for a composite end point as a function of Delta Hepascore calculated at varying time intervals between tests. A: Time between tests - 0 to 12 mo (P = 0.347); B: Time between tests from - 1 year onwards (P = 0.03).